GD2-targeting therapy: a comparative analysis of approaches and promising directions
J Philippova, J Shevchenko, S Sennikov - Frontiers in Immunology, 2024 - frontiersin.org
… In the field of cell therapy, allogeneic immunocompetent cells … It was shown that hu3F8
was 200-fold more effective in … BiAbs, the optimal option was to place the antigen and T-cell …
was 200-fold more effective in … BiAbs, the optimal option was to place the antigen and T-cell …
Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
K Straathof, B Flutter, R Wallace, N Jain… - Science Translational …, 2020 - science.org
… The expression cassette further included the RQR8 sort/“suicide” … engenders highly effective
complement-mediated cell killing (16). … An emerging observation in CAR-T cell therapy is …
complement-mediated cell killing (16). … An emerging observation in CAR-T cell therapy is …
[HTML][HTML] GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma–assessing tumor and T cell interaction
J Sujjitjoon, E Sayour, ST Tsao, M Uiprasertkul… - Translational …, 2021 - Elsevier
… treatments for RB highlight the need for new, safer, and more effective therapeutic options. …
T cell treatment alone may be unable to completely eradicate tumor cells due to tumor cell …
T cell treatment alone may be unable to completely eradicate tumor cells due to tumor cell …
The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL)
U Rovigatti - Cancer Letters, 2021 - Elsevier
… 5.1 Chimeric Antigen Receptor T cell therapy is based on the principle of redirecting T cells
through … still appears to be insufficient and requires further optimization for GD2-CAR-Ts [62]. …
through … still appears to be insufficient and requires further optimization for GD2-CAR-Ts [62]. …
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
… + CAR-NKT subset mediates more potent anti-tumor activity than … In a recent phase 1/2 trial
of GD2-targeting CAR-T cells, … , multi-dosing of cell therapeutics may be required in certain …
of GD2-targeting CAR-T cells, … , multi-dosing of cell therapeutics may be required in certain …
State of the art and perspectives of CAR-T cell therapy for neuroblastoma
D Lutskovich, A Meleshko, M Katsin - Cytotherapy, 2024 - Elsevier
… of CAR-T cell therapy for neuroblastoma has proven safe and … via two distinct CARs are
more effective than the classical in … , antibody selection and optimization to increase recognition …
more effective than the classical in … , antibody selection and optimization to increase recognition …
[图书][B] Engineering and Evaluating Chimeric Antigen Receptor T Cell Potency Ex Vivo and In Vitro
NJ Piscopo - 2020 - search.proquest.com
… reach of CAR T cell therapy has increased with the advent of … modulate medium composition
in situ to optimize cell yields. … cloned a third generation GD2-targeting CAR sequence [162] …
in situ to optimize cell yields. … cloned a third generation GD2-targeting CAR sequence [162] …
Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers
GC Russell, Y Hamzaoui, D Rho, G Sutrave, JS Choi… - Cytotherapy, 2024 - Elsevier
… other moieties to make the CARs more advanced and effective. … , highlighting the need for
further optimization of these systems. … The development of safer yet effective therapy options is …
further optimization of these systems. … The development of safer yet effective therapy options is …
[HTML][HTML] The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
… target toxicity, but also are more effective. We then reviewed the … Currently, there is no
available data on the optimal ABD … Chimeric antigen receptor-Glypican-3 T-cell therapy for …
available data on the optimal ABD … Chimeric antigen receptor-Glypican-3 T-cell therapy for …
Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
M Righi, I Gannon, M Robson, S Srivastava… - Cancer Immunology …, 2023 - AACR
… dFab_CCRs is optimal to improve CAR T-cell expansion, … T-cell therapies, as well as
therapies based on other immune … Each individual DNA barcode cassette was created as DNA g…
therapies based on other immune … Each individual DNA barcode cassette was created as DNA g…